Dysfibrinogenemia
(Redirected from Dysfibrinogenemia, familial)
| Dysfibrinogenemia | |
|---|---|
| Synonyms | |
| Pronounce | N/A |
| Specialty | N/A |
| Symptoms | Abnormal blood clotting, bleeding, thrombosis |
| Complications | Hemorrhage, thromboembolism |
| Onset | |
| Duration | |
| Types | |
| Causes | Genetic mutation in the fibrinogen gene |
| Risks | Family history of the condition |
| Diagnosis | Coagulation test, genetic testing |
| Differential diagnosis | Afibrinogenemia, hypofibrinogenemia |
| Prevention | |
| Treatment | Anticoagulants, fibrinogen concentrate |
| Medication | |
| Prognosis | Variable, depending on severity |
| Frequency | Rare |
| Deaths | |
Dysfibrinogenemia is a rare genetic disorder that affects the blood clotting process. It is characterized by the production of abnormal fibrinogen, a protein that is essential for blood clotting. This condition can lead to either excessive or insufficient blood clotting.
Causes[edit | edit source]
Dysfibrinogenemia is caused by mutations in the FGA, FGB, or FGG genes. These genes provide instructions for making the three different chains of the fibrinogen protein. Mutations in any of these genes can result in the production of abnormal fibrinogen.
Symptoms[edit | edit source]
The symptoms of dysfibrinogenemia can vary widely, even among members of the same family. Some individuals with this condition do not have any symptoms, while others may experience excessive bleeding or abnormal blood clotting. The most common symptoms include nosebleeds, bruising, menorrhagia (heavy menstrual bleeding), and postpartum hemorrhage (heavy bleeding after childbirth).
Diagnosis[edit | edit source]
Diagnosis of dysfibrinogenemia is based on laboratory tests that measure the amount and function of fibrinogen in the blood. Genetic testing can also be used to identify mutations in the FGA, FGB, or FGG genes.
Treatment[edit | edit source]
Treatment for dysfibrinogenemia is aimed at managing the symptoms and preventing complications. This may include medications to control bleeding or prevent blood clots, and in severe cases, fibrinogen replacement therapy.
See also[edit | edit source]
References[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
